REMARKS

Election/Restriction

Claims 1-74 are pending. Restriction has been imposed among the following groups of claims:

```
Group I: Claims 1 (in part), 2-26, 46-52, 60, and 72-74.

Group II: Claims 27-37, 53, 57, 61, and 64-67.

Group III: Claims 38, 39, 54, 58, and 62.

Group IV: Claims 40-45, 55, 59, and 63.

Group V: Claims 1, 68 (in part), and 69.

Group VI: Claims 1, 68 (in part), and 70.

Group VII: Claims 1, 68 (in part), and 71.
```


Applicants provisionally elect, with traverse, to prosecute the subject matter of Group II of the invention encompassing Claims 27-37, 53, 57, 61 and 64-67; drawn to a method of treating, preventing or inhibiting restensis of an artery resulting from vascular injury, employing an aldosterone antagonist classified in class 514, subclass 171, 173 and 174.

Applicants' reasons for traverse are the following:

Each of the pending claims is directed to a method of treatment, inhibition or prevention comprising the administration of an aldosterone antagonist. A search of one restriction group likely will overlap with a search of the other restriction groups. Accordingly, it would not be unduly burdensome on the Office to collectively search the restriction groups.

For these reasons the restriction requirement should be withdrawn.

As requested in the Office action, applicants further provisionally elect, with traverse, the species "eplerenone" as the aldosterone antagonist recited, for example, at page 19, lines 1-7, and described as Compound #1 in Table I at page 13:



Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, methyl ester, $(7\alpha,11\alpha,17\beta)$ -

Claims of Group II encompassing the elected species eplerenone are 27-37, 53, 61 and 64-67.

* * *

Related Application

Applicants point out the following commonly owned, U.S. application:

U.S. Application No. 10/129,759

* * *

The elected Claims 27-37, 53, 57, 61 and 64-67 should now be in condition for allowance. Favorable consideration and early allowance of these claims is requested. The Commissioner is hereby authorized to charge any fees that may be required during the entire pendency of this application, to Deposit Account No. 19-1025.

Respectfully submitted,

Joseph R. Schuh

Joseph R. Schl

Agent for Applicants Registration No. 48,180

PHARMACIA CORPORATION of Pfizer Inc.
Corporate Patent Department P.O. Box 1027
Chesterfield, Missouri 63006
314-274-8182